Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study.

BACKGROUND: Whether or not the use of metformin decreases the risk of gastric adenocarcinoma is unclear.

METHODS: This was a population-based cohort study in 2005-2015. Associations between metformin use and gastric non-cardia and cardia adenocarcinomas were examined within two cohorts; a diabetes cohort of participants using anti-diabetes medications, and a matched cohort of common-medication users, where metformin non-users were frequency matched (10:1) with metformin users for sex and age. Multivariable Cox proportional hazard regression analyses provided hazard ratios (HR) and 95% confidence intervals (CI), adjusting for sex, age, calendar year, comorbidity, Helicobacter pylori eradication treatment, use of non-steroidal anti-inflammatory drugs or aspirin and use of statins.

RESULTS: During the follow-up for a median of 5.8 years, 892 (0.1%) participants in the diabetes cohort and 6395 (0.1%) participants in the matched cohort of common-medication users developed gastric adenocarcinoma. Metformin users had no significantly decreased risk of gastric non-cardia adenocarcinoma (diabetes cohort: HR 0.93, 95% CI 0.78-1.12; matched cohort: HR 1.30, 95% CI 1.18-1.42) or cardia adenocarcinoma (diabetes cohort: HR 1.49, 95% CI 1.09-2.02; matched cohort: HR 1.58, 95% CI 1.38-1.81) compared with non-users in both cohorts.

CONCLUSIONS: This cohort study with <10 years of follow-up suggests metformin use may not prevent gastric adenocarcinoma.